Fig. 6. In vivo anti-tumor efficacy of high-DAR TXCs (A) αCD22/XTEN-May16 and (B) αCD22/XTEN-PBDma18versus corresponding low-DAR TDC controls αCD22/May1.7 and αCD22/PBDma2, respectively. Cubic spline fitted tumor volumes are plotted for each treatment group (n = 5/group) over the duration of study with curves for anti-CD22 TXCs and TDCs in green and blue, respectively, and curves for vehicle and anti-Her2 TXC controls in black and magenta, respectively. Single intravenous doses in nmol kg−1 payload are shown above each curve.
